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Abstract 
Purpose: Despite positive responses in phase II clinical trial’s, the bioreductive 
prodrug Apaziquone failed to achieve statistically significant activity in non-muscle 
invasive bladder cancer in phase III trials. Apaziquone was administered shortly after 
trans-urethral resection and  here we test the hypothesis that haematuria inactivates 
Apaziquone. 
Methods: HPLC analysis was used to determine the ability of human whole blood to 
metabolise Apaziquone ex vivo. An in vitro model of haematuria was developed and 
the response of RT112 and EJ138 cells following a one hour exposure to 
Apaziquone was determined in the presence of urine plus or minus whole blood or 
lysed whole blood. 
Results: HPLC analysis demonstrated that Apaziquone is metabolised by human 
whole blood with a half-life of 78.6  23.0 min. As a model for haematuria, incubation 
of cells in media containing up to 75% buffered (pH 7.4) urine and 25% whole blood 
was not toxic to cells for a one hour exposure period. Whole blood (5% v/v) 
significantly (p < 0.01) reduced the potency of Apaziquone in this experimental 
model. Lysed whole blood also significantly (p < 0.05) reduced cell growth although 
higher concentrations were required to achieve an effect (15% v/v).  
Conclusions: The results of this study demonstrate that haematuria can reduce the 
potency of Apaziquone in this experimental model. These findings impact upon the 
design of further phase III clinical trials and strongly suggest that Apaziquone should 
not be administered immediately after transurethral resection of non-muscle invasive 
bladder cancer when haematuria is common.  
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Introduction 
Apaziquone, originally known as EO9 (3-hydroxy-5-aziridinyl-1- methyl-2-(1H-indole-
4,7-dione)prop-β-en-α-ol) has had a long and chequered history culminating in its 
clinical evaluation against non-muscle invasive bladder cancer [1,2].  Whilst its 
pharmacokinetic properties are undesirable for systemic administration, they are 
paradoxically advantageous in the treatment of non-muscle invasive bladder cancer 
(NMIBC) where intravesical administration ensures adequate delivery to the tumour 
site and any drug leaching out into the blood stream is rapidly removed leading to 
low risk of systemic side effects. Apaziquone is a bioreductive prodrug that requires 
enzymatic activation to DNA damaging species [2] and following the demonstration 
that NMIBC possess the appropriate enzymology to activate Apaziquone [3,4], 
significant ablative activity against NMIBC marker lesions was reported in phase I 
and II clinical trials [5,6]. The level of activity observed in marker lesion studies was 
higher than that reported for other chemotherapy drugs and immune response 
modifiers [7] and two-year response rates demonstrated that long term responses 
were good in comparison to other ablative studies [8,9]. The results of two phase III 
clinical trials were however disappointing and when analysed individually, both 
studies failed to reach statistical significance for the primary endpoint which was the 
two year recurrence rate [10].    
 
To try and explain the stark differences in outcomes between the phase III trial and 
marker lesion studies, we focus in this study on key differences in the design of 
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these clinical trials. The major difference between the two sets of studies was that a 
single dose of Apaziquone was administered intravesically within 24 hours of 
transurethral resection of bladder tumours (TURBT) in phase III studies whereas 
Apaziquone was administered weekly for 6 weeks starting 2 weeks after TURBT in 
the marker lesion studies. There is therefore a difference in the timing of drug 
administration relative to TURBT and a reduction in the cumulative dose given to 
patients in the phase III study. Haematuria is common following surgical resection of 
tumours and in 2002, we demonstrated that Apaziquone is rapidly metabolised by 
murine whole blood [11]. Whilst the context of these studies focused on the design of 
second generation analogues of Apaziquone that had better pharmacokinetic 
properties, this observation has direct relevance to the clinical problem outlined 
above. Administration of Apaziquone immediately after surgery when haematuria is 
common could affect the potency and therefore efficacy of Apaziquone. Post-hoc 
analysis of the data generated in the phase III trial did in fact reveal that a subset of 
patients who received Apaziquone within 30 min of TURBT had no difference in 
response rate compared to the placebo arm [10]. In contrast, patients who received 
Apaziquone between 30 and 90 min after TURBT demonstrated a highly significant 
response to Apaziquone in terms of two-year recurrence rates. Our hypothesis 
therefore is that haematuria immediately after surgery causes a reduction in the 
efficacy of Apaziquone when administered immediately after TURBT. In this study, 
experimental evidence is provided demonstrating that Apaziquone is metabolised by 
human blood and this reduces the potency of Apaziquone in an in vitro model of 
haematuria. These findings have implications for the design of future phase III 
clinical trials and these are discussed within.   
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Materials and Methods 
 
Metabolism of Apaziquone by human blood: The metabolism of Apaziquone by 
human whole blood was performed as described elsewhere [11]. Following informed 
consent, blood samples were obtained from healthy volunteers, collected in EDTA 
tubes (BD vacutainer K2E (EDTA) and either used as ‘whole blood’ or plasma 
(obtained by centrifuging blood at 3000g for 5 min). Whole blood or plasma samples 
were spiked with Apaziquone (20 M) and incubated at 37C for various times. 
Apaziquone was extracted from samples by the addition of ice-cold acetonitrile with 
a solvent/sample ratio of 2:1 and centrifuged at 7000g for 5 min to remove 
precipitated proteins. Samples were analysed by reverse phase HPLC [12] using a 
LiChrosorb RP-18 column and a Waters 996 Photodiode Array detector. The mobile 
phase was phosphate buffer (10mM, pH7.0) / methanol (57/43) and the flow rate 
was 1.2 ml/min. Identical studies were conducted using phosphate buffered saline 
(PBS at pH 7.4). PBS spiked with 20M Apaziquone (t = 0) was used as the 100% 
control and recovery from biological samples was expressed as a percentage of the 
PBS control.      
 
Cell lines and chemosensitivity studies: RT112 and EJ138 human bladder 
carcinoma cell lines were obtained from ECACC and routinely maintained as 
monolayer cultures in RPMI1640/DMEM (50:50 mix) containing foetal calf serum 
(10% v/v) and L-glutamine (2mM). Purified, unformulated Apaziquone was obtained 
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from Spectrum Pharmaceuticals Inc and stock solutions at 100mM were prepared in 
DMSO, aliquoted and stored at -20C. For chemosensitivity studies performed under 
standard cell culture conditions, cells were plated into 96 well plates at 2 x 103 cells 
per well and incubated overnight to adhere. The following day, cell culture media 
was removed and replaced with media containing a range of Apaziquone 
concentrations (10 to 0.196 M using a two-fold serial dilution strategy). Cells were 
exposed to Apaziquone for one hour (to mimic the one hour instillation protocol used 
in the clinic) following which they were washed three times with PBS before the 
addition of 200l of media to each well. Cells were subsequently incubated at 37C 
for 96 hours before growth inhibition determination using the MTT assay as 
described elsewhere [12]. Briefly, culture media was removed from each well and 
replaced with 200l of fresh media prior to the addition of 20l of MTT (5mg/ml). 
Following a 4 hour incubation at 37C, media was removed and formazan crystals 
dissolved in 150l of DMSO per well. The absorbance of the resulting solution was 
determined spectrophotometrically at 540nm and cell growth was determined as the 
true absorbance of treated cells divided by the true absorbance of control cells and 
expressed as a percentage. Three independent experiments were performed and 
the results are presented as the mean IC50 values  standard deviation.   
 
Apaziquone is known to be active against both aerobic and hypoxic cells [13] but all 
studies were conducted against aerobic cells for the following reasons. First, the 
phase III studies were conducted in patients that had all tumours surgically removed 
and therefore there were no solid masses where hypoxia could exist. Second, the 
vehicle used in the instillation was well oxygenated (in equilibrium with atmospheric 
conditions) and the administration of 40ml directly into the bladder would be 
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expected to create local conditions that would be aerobic. Based on the above 
considerations, it would be unlikely that conditions in the bladder would be conducive 
to the hypoxia activation of Apaziquone and this was therefore not evaluated.    
 
Chemosensitivity studies in the presence of urine and whole blood: To 
determine the amount of blood and urine that cells in culture will tolerate, cells were 
exposed to varying amounts of urine or blood for one hour and cell survival was 
determined 96 hours later using the MTT assay as described above. Following 
informed consent, blood samples were obtained from healthy volunteers and placed 
into EDTA tubes. For studies using whole blood, samples were initially diluted 1:1 in 
cell culture media followed for subsequent two-fold serial dilution in media to 
generate a range of blood dilutions (50% to 0.098% v/v). Cell culture plates were set 
up as described above and following a one hour exposure to media containing whole 
blood at different concentrations, cells were washed, culture media added 
(200l/well) and incubated for a further 96 hours before percentage growth inhibition 
was determined using the MTT assay as described above.  In addition, as 
haemolysis is commonly observed in haematuria, similar studies were conducted 
using lysed whole blood (obtained by repeated cycles of rapid freezing in liquid 
nitrogen and thawing at 37C).   
 
Mid-flow urine samples were obtained from healthy volunteers and used 
immediately. Urine samples were either applied directly to cells or pH adjusted to 7.4 
using NaOH prior to addition to cells. Unbuffered or pH adjusted urine was diluted in 
culture media to give a range of urine concentrations and these were applied to cell 
cultures as described above. Following a one hour incubation, cells were washed 
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and culture media added (200l/well). Following a further 96 hour incubation at 37C, 
percentage cell growth was determined using the MTT assay as described above. 
 
 
Results 
 
Metabolism of Apaziquone by whole blood and plasma: The metabolism of 
Apaziquone in human whole blood, human plasma and PBS is presented in figure 
1A. Whilst Apaziquone is stable in PBS and plasma over a 2 hour period, levels of 
Apaziquone decrease significantly in a time dependent manner (figure 1A). No 
metabolites (specifically the inactive products EO5A and EO9-Cl [14]) were observed 
on chromatograms (data not shown) suggesting that any active metabolites of 
Apaziquone are irreversibly bound to cellular components of whole blood and 
remains within the protein precipitate.    
 
Response of EJ138 and RT112 cells to Apaziquone: The response of cell lines 
following a one hour exposure to Apaziquone are presented in figure 1B. Both cell 
lines are sensitive to Apaziquone with IC50 values of 1.11  0.09 and 0.915  
0.291M for RT112 and EJ138 cells respectively. In both cell lines, a one hour 
exposure to Apaziquone at 5 M induces a 95% growth inhibition so this 
concentration was chosen for subsequent experiments to determine the effect of 
blood and urine on the activity of Apaziquone. 
 
Response of EJ138 and RT112 cells to urine and whole blood: The effect of 
whole blood and urine on the proliferation of cells is presented in figure 1C and D 
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respectively. The addition of whole blood onto cells for a period of one hour has no 
effect on cell survival up to 25% v/v. At 50% v/v however, substantial cell kill 
occurred along with problems with clotting in the wells. For subsequent experiments 
therefore, the highest concentration of whole blood used was 25% v/v. Whilst difficult 
to establish the clinical relevance of this concentration of whole blood in these 
experiments, it is known that haematuria following TURBT is both common and can 
vary between mild to gross haematuria that requires further medical intervention [15]. 
Exposure of cells to unbuffered urine (in the experiment in figure 1D, the pH of the 
urine was 5.93) led to a dose dependent reduction in cell growth. Cells were 
however able to tolerate up to 90% urine once pH had been adjusted to pH 7.4. For 
subsequent experiments, pH adjusted urine (pH 7.4) at 75% (v/v) were used.  
 
In summary, the results presented in figures 1B to 1D define the parameters within 
which subsequent experiments were performed. These include (i) the concentration 
of Apaziquone (5 M) that induces >95% cell growth inhibition (ii) an upper limit for 
the amount of whole blood that can be used (25% v/v) without affecting cell growth 
and (iii) the amount of buffered urine that can be used without cause significant 
inhibition of cell growth (75% v/v).  
 
Response of EJ138 and RT112 cells to Apaziquone in buffered urine and whole 
blood: The results presented in figure 2A and B clearly demonstrate that the 
inclusion of whole blood (5%) and buffered urine (75%) significantly (p < 0.01) 
reduces the potency of Apaziquone. Whilst Apaziquone induces a >95% cell kill in 
both RT112 and EJ138 cells in the absence of whole blood, the inclusion of whole 
blood (5% v/v) significantly increases cell survival in RT112 (p = 0.0029) and EJ138 
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(p = 0.0004) cells. The effect of buffered urine on the activity of Apaziquone is 
negligable as cell growth inhibition in the positive controls is similar to cell growth 
inhibition in media (compare figures 2A and B with figure 1B). The results obtained 
using lysed whole blood are presented in figures 2C and D. In both cell lines, a small 
but statistically significant (p < 0.05) reducntion in the potency of Apaziquone was 
observed when lysed whole blood (at concentrations of 15% and above) was added 
to buffered urine. This effect was dose dependent with respect to the amount of 
lysed whole blood included in the assay. In contrast to the whole blood experiments 
where highly significant reductions in activity were observed at 5% whole blood, the 
effect of lysed whole blood on the activity of Apaziquone was lower.   
 
 
Discussion 
 
The main reason for the change in the protocols between Apaziquone phase III and 
marker lesion studies was to comply with current guidance for intravesical 
chemotherapy issued by the European Association of Urology (EAU) and American 
Urological Association (AUA). A series of studies indicate that a single instillation of 
chemotherapy immediately after resection reduces the risk of recurrence [16-19] with 
the most benefit seen with mitomycin C and epirubicin. The EAU guidelines therefore 
recommend immediate intravesical instillation of chemotherapy after surgical 
resection of low to intermediate risk NMIBC. The AUA guidelines differ slightly in that 
intravesical administration of chemotherapy (mitomycin C or epirubicin) should be 
considered within 24 hours of surgical resection for low to intermediate risk NMIBC 
patients. Whilst there is strong clinical evidence for the immediate intravesical 
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administration of mitomycin C or epirubicin after TURBT,  the results of this study 
suggest that the same principles and guidance may not be applicable to Apaziquone.  
 
In contrast to the structurally related mitomycin C which is not metabolised by murine 
whole blood, our previous studies have demonstrated that Apaziquone is rapidly 
metabolised by murine whole blood [11]. In this study we demonstrate that 
Apaziquone is also metabolised by human blood (figure 1A) albeit at a reduced rate 
compared to murine blood. The fact that Apaziquone is stable in both PBS and 
plasma suggests that chemical instability and protein binding are not responsible for 
the loss of Apaziquone. Furthermore, the fact that no metabolites were detected 
using HPLC supports the argument that Apaziquone is being metabolised to 
products that are irreversibly bound to cellular macromolecules that cannot be 
recovered using acetonitrile extraction techniques.  
 
Apaziquone is a prodrug that requires enzymatic activation to generate cytotoxic 
intermediates with one and two electron oxidoreductases playing a prominent role in 
drug activation [2]. The identification of enzymes capable of metabolising 
Apaziquone in human blood has not been elucidated in this study but it is important 
to recognise that the RBC component of whole blood is not just concerned with the 
transport and release of oxygen but it has other metabolic functions that impact upon 
the pharmacokinetic and pharmacodynamic property of drugs including anti-cancer 
agents [20,21]. These metabolic functions extend to redox reactions, nitric oxide 
metabolism and glutathione metabolism [22,23], all of which can affect the 
pharmacology of anti-cancer drugs. Furthermore, red blood cells are known to 
contain high levels of NADH cytochrome b5 reductase (CYB5R), an enzyme that has 
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been implicated in the bioreductive activation of quinone based drugs including 
Mitomycin C [24,25]. A direct role for CYB5R in the activation of Apaziquone has not 
however been established and further studies are required to fully understand the 
detailed metabolism of Apaziquone by human whole blood. The impact of this study 
however resides in the development of an in vitro model of haematuria and the 
demonstration that the efficacy of Apaziquone is reduced under experimental 
conditions that mimic haematuria. This study suggests  that the administration of 
Apaziquone immediately after TURBT when haematuria is common could reduce the 
efficacy of Apaziquone. Whilst the level of haematuria was not reported in phase III 
clinical trials, the presence of whole blood or lysed whole blood in the bladder 
immediately (less than 30 min) after TURBT is a common observation and therefore 
a potential contributing factor that could explain the reduced efficacy of Apaziquone 
observed in phase III clinical trials.  
 
With regards to the continued development of Apaziquone, a further phase III clinical 
trial is required to address the post-hoc analysis of the results and subsequent 
hypotheses generated during the previous phase III studies (FDA briefing 
document). Based on the results of this study, immediate instillation of Apaziquone 
should not be performed with a preference for instillation 60  30 min after surgery 
when haematuria is reduced or non-existent. Another potential way of circumventing 
the effects of haematuria is to increase the dose administered. A dose escalation 
was performed in a clinical pilot study [5] and 4 mg/40ml was selected as the dose 
that induced no systemic or local side effects. This dose was used for all subsequent 
clinical studies including the phase III clinical trials. A dose of 8 mg/40ml induced 
some local toxicities (grade 2/3 dysuria and haematuria) but was also well tolerated.  
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In conclusion, the results of this study have demonstrated that haematuria can 
reduce the efficacy of Apaziquone in experimental models in vitro and this is a 
potential explanation for the poor efficacy of Apaziquone when administered within 
30 min of TURBT. These results were used to inform the design of the current active 
phase III clinical trial (NCT03224182) where Apaziquone is administered 
intravesically 60  30 min after TURBT at a dose of 8 mg/40ml.           
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Figure Legends 
 
Figure 1. Metabolism of Apaziquone by human blood and establishment of the 
haematuria model. Panel A represents the time dependent metabolism of 
Apaziquone following incubation at 37C in whole blood (), plasma () and PBS 
(). Each value represents the mean ± standard deviation for three independent 
experiments. The Response of EJ138 and RT112 cells following a one hour 
exposure to EO9 is presented in panel B. Values represent the mean ± standard 
deviation for three independent experiments. The response of cells to whole blood 
and urine are presented in panels C and D respectively. Exposure times were one 
hour and each result represents the mean ± standard deviation for eight replicates.    
 
Figure 2. Response of RT112 and EJ138 cells to EO9 in the presence and 
absence of whole blood and lysed whole blood. Panels A and B represent the 
response of RT112 and EJ138 respectively to a one hour exposure to Apaziquone (5 
µM) in buffered urine (75% v/v) without (0) or with whole blood (5% v/v). Following 
drug exposure, cell growth was determined 96 hours later using the MTT assay. 
Panels C and D represents RT112 and EJ138 treated with Apaziquone (5μM), urine 
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(75%) and various concentrations of lysed whole blood. Exposure to experimental 
conditions was for one hour followed by a 96 hour recovery period prior to the 
assessment of cell growth using the MTT assay. Control experiments (C) were 
media plus Apaziquone only (no urine or lysed whole blood). Statistical analysis was 
performed using a paired t-test comparing the effects of each treatment with that of 
controls (** and * denote statistical significance at p < 0.01 and p < 0.05 
respectively).   
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